SECTORS TODAY
Tech XLK -4.89%
Financials XLF -0.76%
Healthcare XLV +0.45%
Energy XLE +1.91%
Industrials XLI -1.60%
Cons. Disc. XLY -0.71%
Cons. Staples XLP +1.41%
Utilities XLU +0.67%
Materials XLB +0.40%
Real Estate XLRE +0.26%
Comm. Svcs XLC -1.29%

Earnings release · SHW

The Sherwin-Williams Company Reports 2026 Third Quarter Financial Results

Sherwin Williams Co. · Filed · SEC Form 8-K, Item 2.02

Sherwin Williams Co. company page Original on SEC.gov ↗

Revenue $6.86 billion +7.9% vs a year ago
EPS $3.38 not detected
Guidance revisedoutlook statement
Automated extract. The items below were picked out of the company's press release by software and may be wrong or incomplete. Please read the original before relying on any figure. Not investment advice.

Why it matters

Revenue grew 7.9% year on year to $6.86 billion, and EPS was $3.38. The company revised its guidance; the original release shows which items moved and by how much.

Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.

What the company states

Revenue

$6.86 billion +7.9% vs a year ago

…Consolidated Net sales increased 7.9% to $6.86 billion in the quarter…
EPS

$3.38

…Diluted net income per share increased 0.9% to $3.38 per share in the quarter compared to $3.35 per share in the third quarter of 2025…
Guidance

Guidance revised

…Revising full year 2026 diluted net income per share guidance in the range of $10.92 to $11.22 per share, including Valspar acquisition-related amortization expense of $0.82 per share and severance and other restructuring expenses of $0.11 p | Narrowing full year 2026 adjusted di…

Read the original press release on SEC.gov ↗ Filing index ↗

Disclaimer: This page is generated automatically from public SEC filings for information only. Stocknote does not edit the company's release and does not guarantee the accuracy of the extracted items. Read the full disclaimer here.

Get new research in your inbox

Forensic equity research on US stocks. No spam, unsubscribe anytime.